These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 1274284)

  • 1. [Models and methods used for the selection of antitumor preparations in the USSR and abroad].
    Sof'ina ZP
    Vopr Onkol; 1976; 22(4):82-96. PubMed ID: 1274284
    [No Abstract]   [Full Text] [Related]  

  • 2. Proceedings: Anticancer drug development programs: a comparison of approaches in the United States, the Soviet Union, Japan, and Western Europe.
    Carter SK
    Natl Cancer Inst Monogr; 1974 Feb; 40():31-45. PubMed ID: 4819407
    [No Abstract]   [Full Text] [Related]  

  • 3. Experimental models and their clinical correlations.
    Carter SK; Goldin A
    Natl Cancer Inst Monogr; 1977 Mar; (45):63-74. PubMed ID: 927496
    [No Abstract]   [Full Text] [Related]  

  • 4. Experimental evaluation of antitumor drugs in the USA and USSR and clinical correlations.
    Natl Cancer Inst Monogr; 1980 Dec; (55):1-179. PubMed ID: 7010179
    [No Abstract]   [Full Text] [Related]  

  • 5. [Potentiation of the antitumor action of alkylating compounds by amphotericin B].
    Iaremenko KV; Eremeeva AA; Tereshin IM
    Antibiotiki; 1977; 22(2):153-8. PubMed ID: 404957
    [No Abstract]   [Full Text] [Related]  

  • 6. The National Cancer Institute antitumor drug discovery program, current and future perspectives: a commentary.
    Venditti JM
    Cancer Treat Rep; 1983 Sep; 67(9):767-72. PubMed ID: 6883352
    [No Abstract]   [Full Text] [Related]  

  • 7. [Soviet-American cooperation in experimental and clinical chemotherapy from 1972 to 1979].
    Peredovchikova NI; Kiselev AV; Puchkov IuI; Komarova LE; Gorbunova VA
    Vopr Onkol; 1980; 26(12):3-6. PubMed ID: 7008350
    [No Abstract]   [Full Text] [Related]  

  • 8. Modified protocol for the testing of new synthetics in the L1210 lymphoid leukemia murine model in the DR&D program, DCT, NCI.
    Geran RI; Greenberg NH; Macdonald MM; Abbott BJ
    Natl Cancer Inst Monogr; 1977 Mar; (45):151-3. PubMed ID: 927490
    [No Abstract]   [Full Text] [Related]  

  • 9. A modified screening system to select new cytostatic drugs.
    Kraemer HP; Sedlacek HH
    Behring Inst Mitt; 1984 May; (74):301-28. PubMed ID: 6383326
    [No Abstract]   [Full Text] [Related]  

  • 10. Attempted drug-tumor sensitivity matching using diffusion chamber-cultivated cells.
    Mason BH; Cain BF
    Cancer Treat Rep; 1978 Dec; 62(12):2035-43. PubMed ID: 751713
    [No Abstract]   [Full Text] [Related]  

  • 11. Investigational drugs under study by the United States National Cancer Institute.
    Carter SK; Slavik M
    Cancer Treat Rev; 1976 Mar; 3(1):43-60. PubMed ID: 62615
    [No Abstract]   [Full Text] [Related]  

  • 12. Planning combined therapy--the interaction of experimental and clinical studies.
    Carter SK
    Cancer Chemother Rep 2; 1974 Mar; 4(1):3-11. PubMed ID: 4826498
    [No Abstract]   [Full Text] [Related]  

  • 13. DNA strand damage induced by anticancer agents and its repair in relation to their mode of action in leukemic cells.
    Nakamura T; Sasada M; Tatsumi K
    Nihon Ketsueki Gakkai Zasshi; 1977 Dec; 40(6):1131-44. PubMed ID: 565120
    [No Abstract]   [Full Text] [Related]  

  • 14. Mutagenicity of several classes of antitumor agents to Salmonella typhimurium TA98, TA100, and TA92.
    Seino Y; Nagao M; Yahagi T; Hoshi A; Kawachi T; Sugimura T
    Cancer Res; 1978 Jul; 38(7):2148-56. PubMed ID: 350383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical toxicology protocols of the Laboratory of Toxicology.
    Prieur DJ; Young DM; Davis RD; Cooney DA; Guarino AM
    Natl Cancer Inst Monogr; 1977 Mar; (45):159-77. PubMed ID: 412104
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical development of anticancer agents--a National Cancer Institute perspective.
    Marsoni S; Wittes R
    Cancer Treat Rep; 1984 Jan; 68(1):77-85. PubMed ID: 6362870
    [No Abstract]   [Full Text] [Related]  

  • 17. Proceedings: A comparison of tumour sensitivity to cytostatic agents during in vivo and in vitro culture.
    Bullen BR; Russell CW; Giles GR
    Br J Surg; 1976 Aug; 63(8):660. PubMed ID: 953488
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy.
    Staquet MJ; Byar DP; Green SB; Rozencweig M
    Cancer Treat Rep; 1983 Sep; 67(9):753-65. PubMed ID: 6883351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions.
    Venditti JM; Wesley RA; Plowman J
    Adv Pharmacol Chemother; 1984; 20():1-20. PubMed ID: 6398966
    [No Abstract]   [Full Text] [Related]  

  • 20. The preclinical new drug research program of the National Cancer Institute.
    Driscoll JS
    Cancer Treat Rep; 1984 Jan; 68(1):63-76. PubMed ID: 6692438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.